LLY vs PATH · P/E 39, rev $65.18B vs P/E 19, rev $1.61B
Eli Lilly and Company (LLY) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LLY and PATH stock pages for the full models.
Not investment advice.